# A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

> **NCT05489289** · PHASE3 · RECRUITING · sponsor: **Akeso** · enrollment: 570 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** AK104
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT05489289
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-05
- **Primary completion:** 2026-01-28
- **Final completion:** 2027-01-01
- **Target enrollment:** 570 (ESTIMATED)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05489289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05489289, "A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05489289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*